While anti-EGFR therapy was associated with a higher likelihood of tumor fibrosis ≥40% compared to anti-VEGF therapy, this did not result in improved overall survival among patients undergoing resection of hepatic M1 metastases from metastatic colorectal cancer (mCRC). Here, VEGFA is linked to metastatic colorectal cancer.